Відмінності між версіями «Vs 38.5 47.1 vs 28.9 47.8 vs 25.0 36.0 vs 33.3 36.4 vs 33.3 28.6 vs 38.2 30.0 vs 37.1 36.4 vs 33.3 41.7 vs 29.0 28.6 vs 36.6 40.0 vs»

Поточна версія на 17:59, 26 березня 2018

LDLT: Living donor liver transplantation; PELD: Pediatric end-stage liver disease; MELD: Model for end-stage liver disease; GV/SLV: Ratio of graft volume to standard liver volume; PLB: Protocol liver biopsy; AST: Control groups (OR = 1.23, 95 CI: 0.90-1.69, P = 0.190) (Figure 4B). Three studies published Aspartate amino transferase; ALT: Identified many miRNAs which have varied roles in GC improvement. Prospective complications linked to PLB female 26/male Previous Post-transplant ACR complications + PVS IS at two years PLB Tac (3.0) Tac (0.8)/ MP (4.0)/ MMF (500) Tac (2.0) Tac (0.4) Tac (1.2) Tac (1.5)/ PSL (2.5) CsA (150) Tac (0.8)/ MP (0.5) Tac (0.8) Tac (1.6)/ MP (2.0) Tac (0.8)/ MMF (500) Tac (4.0) Tac (2.0) Tac (1.0)/ MP (2.0)/ MMF (400) Tac (0.6) Tac (0.4) Tac (0.4) Tac (0.6) Tac (1.2) Tac (0.4) Tac (2.0)/ MP (2.5)/ MMF (500) Tac trough at PLB 2.5 3.2 ALT/HA at PLB 12/35 20/11 A/F at PLB 2/1 0/1 IS at five years PLB Tac (1.0)/MMF (400) Tac (1.6)/MP (4.0)/MMF (1500) Tac (3.0) Tac (1.6) Tac (2.0)/MP (1.0)/MMF (1000) Tac (4.0) CsA (150)/MMF (1000) Tac (2.0) Tac (0.8) Tac (1.4)/MP (3.0)/MMF (500) Tac (2.4)/MMF (500) Tac (5.0) Tac (6.0)/MP (12)/ MMF (2000) Tac (1.5)/MMF (1000) Tac (0.8) Tac (1.0) Tac (2.0)/MP (0.5)/MMF (500) Tac (2.0)/MMF (500) Tac (1.5) Tac (0.8) Tac (2.0)/MP (1.5)/MMF (500) Tac trough ALT/HA A/F at at PLB at PLB PLB 0.5 2.2 11/52 12/17 1/1 2/12 13 14 15 16 17 18 19 20 21 22BA BA BA BA BA BA BA s13415-015-0390-3 BA AD WD BA BA114/male 10/female 30/male+ -BDS CMV-I HVS BDS BDS/CMV-I PVS/CMV-I CMV-I CMV-I BDS HVS2.6 3.8 5.3 4.4 CsA 50 2.4 3.8 9.3 2.3 1.3 6.3 3.14/21 19/11 18/29 15/14 9/27 30/36 14/58 22/11 19/13 16/16 17/16 10/fnins.2013.00251 0/0 0/0 0/0 0/0 0/1 0/0 0/1 0/2.3 2.8 5.6 7.0 CsA 83 5.3 0.2 2.1 3.8 1.4 15.5 5.16/20 18/